BioNTech price target raised to $185 from $181 at Clear Street

Clear Street raised the firm’s price target on BioNTech (BNTX) to $185 from $181 and keeps a Buy rating on the shares after updating the firm’s model to a year-end 2026 valuation following the company reporting Q2 results this morning. The company remains on track to report Phase 2 dose optimization results from BNT327 studies in small cell lung cancer and triple negative breast cancer in the second half of 2025, notes the analyst, who calls the company’s oncology pipeline “underappreciated.”